M. Gonzalez-Edick

Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy

K. Jooss, T. Harding, G. Tu, 2010, Cancer Immunology, Immunotherapy.

AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma.

D. Deen, T. Ozawa, K. Jooss, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors.

K. Jooss, T. Harding, P. Dickinson, 2006, Human gene therapy.

Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer.

T. Clackson, V. Rivera, K. Jooss, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action

M. Moskalenko, K. Jooss, M. Vanroey, 2007, Cancer Immunology, Immunotherapy.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

M. Moskalenko, K. Jooss, M. Vanroey, 2009, Clinical immunology.

Intratumoral Coadministration of Hyaluronidase Enzyme and Oncolytic Adenoviruses Enhances Virus Potency in Metastatic Tumor Models

M. van Roey, K. Jooss, S. Ganesh, 2008, Clinical Cancer Research.

Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.

M. van Roey, K. Jooss, S. Ganesh, 2009, Human gene therapy.

Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer

Y. Ge, K. Jooss, S. Ganesh, 2009, Cancer Gene Therapy.